Cargando…
DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
Somatic mutations in the EGFR proto-oncogene occur in ~15% of human lung adenocarcinomas and the importance of EGFR mutations for the initiation and maintenance of lung cancer is well established from mouse models and cancer therapy trials in human lung cancer patients. Recently, we identified DOK2...
Autores principales: | Berger, Alice H., Chen, Ming, Morotti, Alessandro, Janas, Justyna A., Niki, Masaru, Bronson, Roderick T., Taylor, Barry S., Ladanyi, Marc, Van Aelst, Linda, Politi, Katerina, Varmus, Harold E., Pandolfi, Pier Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821857/ https://www.ncbi.nlm.nih.gov/pubmed/24255704 http://dx.doi.org/10.1371/journal.pone.0079526 |
Ejemplares similares
-
Role of Dok-1 and Dok-2 in Leukemia Suppression
por: Niki, Masaru, et al.
Publicado: (2004) -
P62(dok), a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210(bcr-abl)
por: Di Cristofano, Antonio, et al.
Publicado: (2001) -
Phosphoinositide 3-Kinase–Dependent Membrane Recruitment of P62(dok) Is Essential for Its Negative Effect on Mitogen-Activated Protein (Map) Kinase Activation
por: Zhao, Mingming, et al.
Publicado: (2001) -
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005) -
c-Abl phosphorylates Dok1 to promote filopodia during cell spreading
por: Woodring, Pamela J., et al.
Publicado: (2004)